India, Feb. 7 -- AbbVie (ABBV) announced the U.S. Food and Drug Administration approval of Emblaveo (aztreonam and avibactam). This marks the first fixed-dose, intravenous monobactam/ Beta -lactamase inhibitor combination antibiotic. In combination with metronidazole, Emblaveo is approved for patients aged 18 and older who have limited or no alternative options for treating complicated intra-abdominal infections (cIAI). It is effective against several susceptible Gram-negative microorganisms, including Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae complex, Citrobacter freundii complex, and Serratia marcescens.
According to the company, Emblaveo will be available for commercial use in the U.S. in third qu...